Mammalian C to U RNA is mediated by APOBEC1, the catalytic deaminase, together with RNA binding cofactors (including A1CF and RBM47) whose relative physiological requirements are unresolved. Although A1CF complements APOBEC1 for in vitro RNA editing, A1cf -/mice exhibited no change in apolipoproteinB (apoB) RNA editing, while Rbm47 mutant mice exhibited impaired intestinal RNA editing of apoB as well as other targets. Here we examined the role of A1CF and RBM47 in adult mouse liver and intestine, following deletion of either one or both gene products and also following forced (liver or intestinal) transgenic A1CF expression. There were minimal changes in hepatic and intestinal apoB RNA editing in A1cf -/mice and no changes in either liver-or intestine-specific A1CF transgenic mice. Rbm47 liver-specific knockout (Rbm47 LKO ) mice demonstrated reduced editing in a subset (11 of 20) of RNA targets, including apoB. By contrast, apoB RNA editing was virtually eliminated (<6% activity) in intestine-specific (Rbm47 IKO ) mice with only five of 53 targets exhibiting C-to-U RNA editing. Double knockout of A1cf and Rbm47 in liver (AR LKO ) eliminated apoB RNA editing and reduced editing in the majority of other targets, with no changes following adenoviral APOBEC1 administration. Intestinal double knockout mice (AR IKO ) demonstrated further reduced editing (<10% activity) in four of five of the residual APOBEC1 targets identified in AR IKO mice. These data suggest that A1CF and RBM47 each function independently, yet interact in a tissue-specific manner, to regulate the activity and site selection of APOBEC1 dependent C-to-U RNA editing.
INTRODUCTION
Mammalian RNA editing encompasses a process in which select sequences within the original genomic template are enzymatically altered to produce a change in the corresponding RNA transcript (for review, see Gagnidze et al. 2018) . By far the most prevalent form of RNA editing is adenosine to inosine deamination (A-to-I), which is mediated by members of the family of adenosine deaminases acting on RNA (ADARs) (for review, see Nishikura 2010; Keegan et al. 2017) . ADAR-mediated RNA editing requires optimal configuration of sites within a double-stranded RNA substrate, most typically residing within intronic or intergenic regions enriched in Alu repeats (Nishikura 2010) . The other, less prevalent form of RNA editing involves cytidine to uridine deamination (C-to-U) of singlestrand RNA substrates, which is mediated by APOBEC1, and was first described 30 yr ago as the molecular mechanism underlying the tissue-specific production of two distinct isoforms of the lipid transport protein, apolipopro-teinB (apoB), from the liver and small intestine (Chen et al. 1987; Powell et al. 1987) . Genetic deletion and rescue experiments have demonstrated that the catalytic deaminase, APOBEC1, is absolutely required for apoB C-to-U RNA editing (Hirano et al. 1996; Nakamuta et al. 1996) , but those experiments also revealed that additional factor(s) are required since APOBEC1 alone was insufficient to mediate C-to-U RNA editing on synthetic apoB RNA templates (Driscoll et al. 1993; Sowden et al. 1996b; Anant et al. 2003) .
In 2000, two groups simultaneously reported the identification of a plausible complementation factor, APOBEC1 complementation factor (A1CF), demonstrating that a twocomponent system containing recombinant A1CF and APOBEC1 alone was sufficient for efficient C-to-U RNA editing of apoB RNA in vitro (Lellek et al. 2000; Mehta et al. 2000) . However, formal evidence of the role and requisite physiological functions for A1CF in vivo, including its role in C-to-U RNA editing, has been challenging to elucidate and those efforts have yielded somewhat conflicting results. Earlier studies demonstrated early embryonic lethality in germline A1cf −/− mice with null embryos failing to implant at E3.5d (Blanc et al. 2005) . However, heterozygous A1cf +/− mice were viable and exhibited defective liver regeneration following partial hepatectomy, but no change in intestinal apoB RNA editing and showed, if anything, a subtle increase in hepatic apoB RNA editing . More recently, another line of A1cf −/− mice was reported, that used a different gene targeting strategy, and bypassed the early embryonic lethality reported with the first line (Snyder et al. 2017) . Those A1cf −/− mice were viable as adults, with no overt growth phenotype in either liver or intestine and exhibited no change in either apoB RNA editing or in several other candidate RNAs that were identified from reports of a range of APOBEC1 targets of C-to-U editing (Rosenberg et al. 2011; Blanc et al. 2014) . Those findings in adult A1cf −/− mice (Snyder et al. 2017) suggested that A1CF is dispensable for apoB RNA editing and raised the possibility that A1CF may not participate in regulating C-to-U RNA editing activity of other physiological targets.
An alternative candidate complementation factor, RBM47, was identified in a screen of genes in foregut endoderm (Loebel et al. 2011) , and a role in apoB RNA editing emerged with the discovery that gene-trap Rbm47 mutant mice exhibited prenatal lethality with surviving pups exhibiting defective C-to-U editing of intestinal apoB RNA and several other targets (Fossat et al. 2014) . In particular, based on the loss of C-to-U RNA editing activity in the surviving Rbm47 mutant pups, we wondered what functions might be impaired in adult Rbm47 null mice where conditional targeting approaches might bypass the severe perinatal, developmental defects?
Here we examined the role of A1CF and of RBM47 in physiological, tissue-specific regulation of C-to-U RNA editing, both individually and in combination, in order to examine the range of target specificity and activity in vivo for each of these potential complementation factors. The findings suggest a model in which both A1CF and RBM47 exhibit distinctive, tissue-specific functions that together modulate APOBEC1 dependent RNA editing site selection and activity.
RESULTS

Subtle changes in apoB RNA editing following A1CF deletion and transgenic A1CF overexpression
We replicated the recent findings (Snyder et al. 2017 ) that A1cf −/− mice show no A1CF protein expression in liver ( Fig. 1A,B ) with only minor alterations in apoB RNA editing (65% vs. 53%, Fig. 1C ) and no change in the ratio of apoB100 vs. apoB48 protein products ( Fig. 1D ). There was a small (albeit statistically significant) increase in apoB RNA editing (84%, Fig. 1C ), with no change in hepatic apoB100/48 ratio ( Fig. 1E ) with liver-transgenic A1CF overexpression (approximately fourfold overexpression, Fig. 1F ). Since prior studies have shown that overexpression of APOBEC1 results in promiscuous editing of apoB RNA, beyond the canonical site (Sowden et al. 1996a; Yamanaka et al. 1996) , we examined the impact of adenoviral APOBEC1 (Ad-A1) overexpression in either A1cf −/− mice deletion or with liver transgenic A1CF overexpression. Those findings revealed increased RNA editing at the canonical site (6666) in all genotypes but generally decreased or absent editing at downstream sites in both transgenic A1cf and A1cf −/− mice ( Fig. 1G ).
We extended those findings in small intestine, comparing A1cf −/− mice to those with intestinal transgenic A1CF overexpression (approximately fourfold overexpression, Fig. 2A ). We observed no alteration in canonical site editing of apoB RNA by genotype but again observed decreased editing at downstream sites in both transgenic A1CF and A1cf −/− mice (Fig. 2B ). Taken together, the findings suggest that basal hepatic apoB RNA editing at the canonical site exhibits minor changes over a range of A1CF expression. Under conditions of forced APOBEC1 overexpression, all genotypes exhibited virtually 100% RNA editing at the canonical site with subtle alterations in editing activity at downstream sites in the setting of either loss of A1CF or with transgenic A1CF overexpression. By contrast, there was no change in intestinal apoB RNA editing activity (versus WT) at the canonical site in either transgenic A1CF or A1cf −/− mice.
Tissue-specific Rbm47 deletion differentially impairs apoB RNA editing in liver and intestine Earlier observations in Rbm47 mutant mice demonstrated prenatal lethality (Fossat et al. 2014) , making it challenging to understand the role of RBM47 in RNA editing in adult animals. This is an important consideration in examining apoB RNA editing activity, since work has demonstrated that apoB RNA editing is developmentally regulated in a tissue-specific manner in rodents and other mammals, including humans (Teng et al. 1990a,b; Inui et al. 1992) . Accordingly, we generated conditional Rbm47 floxed mice ( Fig. 3A and Methods) and crossed them into either Albumin-Cre (Jax) or Villin-Cre (Jax) transgenic mice to generate liver-specific (Rbm47 LKO , Fig. 3B ,C) and intestine-specific (Rbm47 IKO , Fig. 3D ) mice, respectively, both of which were viable as adults. We then examined apoB RNA editing in the respective tissues, the findings demonstrating that hepatic apoB RNA editing in Rbm47 LKO mice was reduced (∼25% C-to-U editing at the canonical site) but not eliminated, while intestinal apoB RNA editing was virtually eliminated in Rbm47 IKO mice (6% residual activity) at the canonical site ( Fig. 3E , F). Accompanying these changes in RNA editing activity there was a corresponding increase in relative hepatic apoB100 vs. apoB48 protein expression ( Fig. 3G) , with no change in hepatic A1CF expression in Rbm47 LKO mice ( Fig. 3H ), suggesting that Rbm47 deletion does not produce a compensatory change in total A1CF abundance.
We then examined the response to adenoviral APOBEC1 (Ad-A1) overexpression in Rbm47 LKO mice, the findings demonstrating no change in apoB RNA editing activity at the canonical site (6666) in Rbm47 LKO mice ( Fig. 3I , ∼30% editing with Ad-A1 vs. ∼25% editing at baseline, as in Fig.  3E ), suggesting that hepatic RNA editing activity is constrained even with supplemental Apobec-1.
These findings together suggest that RBM47 is required for intestinal apoB RNA editing in adult mice, because Rbm47 deletion essentially eliminates editing activity. By contrast, the findings suggest the possibility that A1CF alone provides basal complementation for hepatic APOBEC1 dependent RNA editing activity (i.e., in the absence of RBM47) while suggesting that potential stoichiometric interactions between A1CF and RBM47 are required to establish physiologic hepatic apoB RNA editing.
Combined hepatic deletion of A1cf and of Rbm47 eliminates hepatic apoB RNA editing and is partially restored with A1CF rescue, both in vivo and in vitro Based on the suggestion above, we crossed Rbm47 LKO mice with A1cf −/− mice to generate mice with combined deletion of both genes in the liver, referred to as AR LKO mice. As expected, those AR LKO mice demonstrated loss of both A1CF and RBM47 in liver ( Fig. 4A ), but we observed that (C ) Hepatic apoB RNA editing by genotype. The region of apoB sequenced spans nucleotides 6563 to 7210. The data represent the average from three to four mice per genotype. Twenty clones were sequenced for each mouse. Positions of the edited cytidines are indicated on the left. Every circle represents a sequenced clone. Solid circles indicate C to U editing at the specified cytidine base, position indicated on the left. In all three genotypes, C to U editing is detected only at apoB canonical site C6666. Editing frequency (% edited clones at cytidine 6666) is indicated to the right. The numbers in parentheses under each panel represent the number of edited clones versus the total number of sequenced clones. The P-value under each panel indicates that editing at the canonical site of ApoB is statistically significant between A1cf −/− and WT liver; between A1cf −/− and A1cf Tg ; between A1cf Tg and WT liver. Editing frequency at canonical C6666 editing site as mean ± SE: WT: 64 ± 4.2; A1cf −/− 53 ± 1.8; A1cf Tg 84.5 ± 1.8. (D) Western blot detection of ApoB100 and ApoB48 in WT and A1cf −/− livers. Detection of Actin is used as loading control (n = 5-7 per genotype). (E) Western blot analysis of apoB100:B48 ratio in WT and transgenic A1CF liver (n = 3 per genotype). Actin is used as loading control. (F) A1CF and APOBEC1 expression in WT, A1cf −/− , and Acf Tg mice injected with adenovirus-Apobec-1. Actin is used as loading control. (G) Hyperediting profile of hepatic ApoB RNA following adenoviral-expression of Apobec-1 in WT, A1cf −/− and A1cf Tg mice. Representative data from three to four mice per genotype. Twenty clones per mouse were sequenced. Positions of the edited cytidines are indicated on the left. Editing frequencies at specific cytidine positions are shown to the right.
hepatic A1CF appeared more abundant by western blotting than RBM47, an impression confirmed at the RNA level as shown by quantitative PCR (Fig. 4B ). We next examined those AR LKO mice under basal conditions (chow fed) or following Ad-A1 administration (discussed below) to supplement basal expression of APOBEC1 (Fig. 4A ). The findings at baseline in adult AR LKO mice indicate no change in total apoB mRNA abundance ( Fig. 4C) , with elimination of apoB RNA editing (<1%, Table 1 ) and no detectable apoB48 in liver protein extracts ( Fig. 4D ). Editing activity of other targets is presented in a subsequent section below.
To examine the possibility that A1CF might exert an RBM47-independent role in hepatic apoB RNA editing, we administered adenoviral A1CF (Ad-A1CF) to AR LKO mice. Those AR LKO mice, injected intravenously with Ad-A1CF, expressed hepatic A1CF ( Fig. 4E ) and revealed partial restoration of apoB RNA editing (∼6% activity, Fig. 4E ). We further examined the role of A1CF using an in vitro RNA editing assay and a synthetic apoB RNA template (Blanc et al. 2001) in the presence of S100 extracts prepared from liver of wild-type or AR LKO mice, supplemented, where indicated, with either recombinant A1CF or RBM47 as previously described . S100 extracts prepared from wild-type mice produced robust C-to-U editing of apoB (Fig. 4E , lane 2) while extracts from AR LKO mice were inactive (Fig. 4F, lane 3) . However, supplementing extracts from AR LKO mice with recombinant A1CF partially restored editing activity, albeit not to the level observed in extracts from wild-type mice (Fig. 4F , lanes 4,5 vs. lane 2). Similarly, supplementing extracts from AR LKO mice with recombinant RBM47 restored only modest editing activity ( Fig. 4F , lanes 6-9). Those findings suggest that S100 extracts from the liver of AR LKO mice are devoid of C-to-U RNA editing activity, but that the addition of either recombinant A1CF or RBM47 proteins alone produces partial restoration. We confirmed observations that recombinant A1CF alone with recombinant APOBEC1 yields robust editing activity, (Fig. 4F, lane 9) , and also that recombinant RBM47 with recombinant APOBEC1 yielded editing activity (Fig. 4F, lane 10) . Those findings suggest that either recombinant A1CF or RBM47 provide complementation activity to recombinant APOBEC1 in editing apoB RNA in vitro and support the earlier observations regarding A1CF function (Mehta and Driscoll 2002) . Previous work has suggested that there was no additional effect on apoB RNA editing activity following supplementation of in vitro reactions containing APOBEC1 with both RBM47 and A1CF (Fossat et al. 2014 ) but we did not independently explore this question.
Combined hepatic deletion of A1cf and of Rbm47 modifies RNA activity of a subset of targets
Based on the finding that hepatic apoB RNA editing was reduced but not eliminated in Rbm47 LKO mice, we examined C-to-U RNA editing efficiency across the range of previously identified hepatic targets (Blanc et al. 2014) , in the four genotypes (WT, A1cf −/− , Rbm47 LKO , and AR LKO ). The findings show that deletion of A1cf alone failed to alter editing activity in any of 21 targets examined (Table 1) . By contrast, hepatic C-to-U RNA editing efficiency in Rbm47 LKO mice was decreased (average of 64%, range 44%-84%), but not eliminated, in 11 targets (including apoB), unchanged in four targets (Table 1 ) and, to our surprise, increased in four targets (Table 1) . Of those four targets whose C-to-U RNA editing efficiency was increased in Rbm47 LKO mice, all showed decreased editing in AR LKO mice (including to <1% in Cmtm6, Sh3bgrl, and Rnf128), suggesting that these particular lossof-function effects of hepatic Rbm47 deletion also require loss of A1CF. In addition, there was a further subset of targets (including Sep15, Mpeg, and Cybb) whose editing activity was either unchanged or only slightly decreased in AR LKO mice (Table 1) . A summary figure of the proposed hierarchy for A1CF, RBM47 and the combination (A1CF plus RBM47) in hepatic C-to-U RNA editing is presented in Figure 4G .
Combined intestinal deletion of both A1cf and Rbm47 eliminates C-to-U RNA editing in the majority of RNAs and reveals tissuespecific roles in target selection
The findings above indicate a distinct tissue-specific requirement for RBM47, since hepatic apoB RNA editing was reduced but not eliminated in Rbm47 LKO mice (Fig. 3E ), while apoB RNA editing was virtually eliminated in Rbm47 IKO mice (Fig. 3F ). Accordingly, we examined the possibility that editing at other RNA target sites was altered in Rbm47 IKO mice. The findings indicate that the majority (48/53) of targets exhibited >90% reduction in RNA editing activity in Rbm47 IKO mice (Table 2) , including four targets (B2M, Cmtm6, Rnf128 and Sh3bgrl) where (hepatic) RNA editing activity was found to be increased in Rbm47 LKO mice (compare data in Table 1, vs. Table 2 ). While RNA editing was reduced in the majority of targets in Rbm47 IKO mice, we identified five targets (Cyp4v3, Kctd12, Tmbim6, Sep15, and Bche) with significant residual editing activity (Table 2 ). In order to examine the impact of combined loss of A1CF and RBM47 in adult intestine, we crossed Rbm47 IKO mice with A1cf −/− mice to generate mice with combined deletion referred to as AR IKO mice (Fig. 5A ). As expected, AR IKO mice exhibited no apoB RNA editing at any of the previously identified sites (Fig. 5B ), and no change in total intestinal apoB mRNA abundance was observed in any genotype (Fig. 5C ). We then examined editing activity in AR IKO mice in the five targets identified above demonstrating residual editing activity in Rbm47 IKO mice. Those findings demonstrated decreased editing activity in four of five targets with one (Kctd12) exhibiting 30% C-to-U RNA editing, despite the absence of both A1CF and RBM47. These findings strongly suggest that RBM47 plays a dominant role in regulating Apobec-1 dependent RNA editing in mouse intestine, but also support the conclusions that A1CF plays a permissive role in a subset of targets. The one exception was C-to-U RNA editing of Kctd12, which was uninfluenced by the loss of either complementation factor.
DISCUSSION
There is considerable information regarding the physiological regulation of mammalian C-to-U RNA editing, particularly for the prototype target apoB RNA, which undergoes tissuespecific regulation, modulated by developmental, hormonal, and nutritional cues in mouse and rat liver, through mechanisms proposed to involve regulation of the complementation factors (Teng et al. 1990a; Inui et al. 1992 Inui et al. , 1994 Lau et al. 1995; Lehmann et al. 2006 ). In addition, intestinal apoB RNA editing is developmentally regulated in both mouse and human small intestine, findings at least partially accounted for by the temporal patterns of APOBEC1 expression but which may also reflect alterations in A1CF activity (Teng et al. 1990b; Giannoni et al. 1995) . These earlier studies, coupled with findings showing that A1CF undergoes alternative splicing with differential functions assigned to each splice form , supported the view that A1CF undergoes nuclearcytoplasmic shuttling in conjunction with metabolically regulated, posttranslational modifications that in turn regulate C-to-U RNA editing . The view -8) . ApoB RNA editing was determined by poison primer extension (Materials and Methods). The relative mobility of the unedited (C) and the edited (U) C6666 is indicated to the right. Representative of three independent assays. (G) Baseline hepatic editing efficiency of 3 ′ UTR APOBEC1 RNA targets and hierarchy of RNA binding complementation factors (see Table 1 for data). Wild-type (black dots), Rbm47 LKO (green dots), A1cf −/− (blue dots), AR LKO (orange dots), and Apobec1 −/− (white dots). RNAs preferentially edited by RBM47 show decreased editing efficiency in Rbm47 LKO and AR LKO and no change in A1cf −/− . In contrast, RNAs preferentially edited by A1CF show no change in the absence of A1CF but increased editing frequency in the absence of RBM47 and almost complete loss of editing in the absence of both A1CF and RBM47.
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Cold Spring Harbor Laboratory Press on January 11, 2019 -Published by rnajournal.cshlp.org Downloaded from that A1CF was a necessary cofactor for C-to-U RNA editing was radically revised with the report that Rbm47 mutant mice exhibit virtually no intestinal apoB RNA editing and also that a two-component system containing recombinant RBM47 with recombinant APOBEC1 together catalyze in vitro apoB RNA editing (Fossat et al. 2014) . Those findings, coupled with the recent report that A1cf −/− mice exhibit no detectable alterations in C-to-U RNA editing (Snyder et al. 2017 ), led to the alternative suggestion that RBM47 acts alone as the complementation factor for APOBEC1 dependent RNA editing, and left open the function (if any) for A1CF in vivo. The findings from this report offer a more nuanced view, namely, that A1CF and RBM47 function independently, yet interact in a tissuespecific manner to regulate the activity and site selection of Apobec-1 dependent C-to-U RNA editing in adult mouse intestine and liver. Several aspects of this report merit further discussion.
A1CF was independently identified by two groups, through approaches based in part on RNA binding affinity of factors purified from either baboon or rat liver that were enriched by binding to an apoB RNA fragment flanking the C-to-U editing site, which eventually yielded a single protein that exhibited complementation activity for in vitro apoB RNA editing (Lellek et al. 2000; Mehta et al. 2000) . Those findings, coupled with findings that RBM47 colocalizes and physically interacts with both APOBEC1 and with A1CF (Fossat et al. 2014) suggest that the in-vivo complementation activity originally assigned to A1CF may reflect the optimal configuration of RBM47 and APOBEC1in the context of a heteromeric, functional editosome complex, containing A1CF (Fossat et al. 2014) . By contrast, the structural and functional homology of A1CF and RBM47 likely accounts for the ability of either protein to provide complementation activity in a reconstituted, two component in vitro assay (Fossat et al. 2014) and Figure 4F . These observations allow us in principle to reconcile the apparent paradox that A1CF alone with APOBEC1 is sufficient for in vitro RNA editing yet appears dispensable for physiological editing activity in vivo.
Based on the finding that Rbm47 mutant mice exhibit virtually no intestinal apoB RNA editing in the surviving animals (Fossat et al. 2014) , we expected to find that hepatic apoB RNA editing would be similarly eliminated in Rbm47 LKO mice. However, that was not the case. We observed instead that RNA editing was reduced but not eliminated in Rbm47 LKO mice and that both isoforms of apoB were readily detectable, albeit with an altered ratio reflecting the decreased RNA editing activity. Similarly, we observed decreased activity in 11 of 20 other targets of C-to-U RNA editing in those Rbm47 LKO mice, no change in a further subset and an increase in yet another subset of four targets (B2m, Cmtm6, Sh3bgrl, Rnf128, Table 1 ). We interpret those findings to indicate that RBM47 provides the dominant source of complementation activity for the 11 of 20 targets that exhibit decreased editing in Rbm47 LKO mice, while the subset of four targets showing increased editing activity in Rbm47 LKO mice may be predominantly A1CF dependent, as evidenced by the loss of editing activity in AR LKO mice. The additional subset of hepatic targets demonstrating ∼12%-14% residual editing activity in AR LKO mice (Table 1) might conceivably reflect residual expression of A1CF or RBM47 within non-parenchymal cells (Kupffer cells, stellate cells, endothelial cells, or cholangiocytes), which would not be amenable to Cre deletion with the albumin promoter used in these studies, which is reportedly hepatocyte predominant (Postic et al. 1999) .
The same caveats might be considered for the findings with Rbm47 IKO mice where a small subset of targets exhibited residual editing activity, most of which were further reduced in AR IKO mice. Those studies were conducted using scraped intestinal mucosa which contains >90% enterocytes but may also include submucosal and lamina propria cell types, including neuronal cells. It is worth noting that the villin promoter, used to drive intestinal Cre expression in our studies, is reported to be confined to villus enterocytes and colonocytes with some expression in renal tubular cells (el Marjou et al. 2004 ). This cell-restricted pattern of villin-Cre expression may be a relevant consideration for the observations regarding RNA editing of Kctd12, which demonstrated robust (30%) Apobec-1 dependent editing in AR IKO mice. Kctd12 encodes a potassium channel which is known to be widely expressed in human and mouse tissues including in intestinal neuroendocrine and colorectal tumors as well as throughout the brain (Resendes et al. 2004; Li et al. 2016; Suehara et al. 2018 ). Thus, it is possible that Kctd12 expression in cells other than enterocytes might account for the preserved RNA editing activity in Rbm47 IKO and AR IKO mice. Nevertheless, an alternative interpretation might also be considered, namely that other (to be identified) complementation factors might be responsible. A further consideration is that Apobec-1 alone may be sufficient to mediate C-to-U RNA editing of a small subset of transcripts, as implied earlier (Chester et al. 2004 ). Resolution of these possibilities will require further investigation beyond the scope of the current studies.
The tissue-specific roles of A1CF and RBM47 in RNA editing was further supported by the finding that four hepatic targets (B2m, Cmtm6, Sh3bgrl Rnf128) that were edited more efficiently by A1CF in the liver (Table 1) were edited only by RBM47 in the intestine (Table 2) . One possibility to explain this apparent discrepancy is that the binding site(s) in those RNAs for A1CF may not be as accessible in the intestine as in the liver, perhaps because the folding of RNAs may be different and/or there may be other RBPs that in turn modify access of target transcripts to A1CF. The identification of A1CF/RNA/ protein partners will require extended investigation beyond the focus of this study.
The proposed dominance of RBM47 in hepatic apoB RNA editing is further supported by the observation that hepatic A1CF appears to be expressed at higher levels than RBM47 (Fig. 4A ) while loss of A1CF alone exerts only minor if any effect on apoB RNA editing. This may imply either greater affinity or sustained occupancy with an RBM47-apoB RNA-APOBEC1 complex compared to an A1CF-apoB RNA-APOBEC1 complex. It is also conceivable that both RBM47-Apobec-1 and A1CF-APOBEC1 complexes coexist, with RBM47-APOBEC1 complex being more efficient in mediating RNA editing, but this speculation will require formal examination and a more complete understanding of the relative molar distribution of each cofactor within these complexes.
The current findings also raise the question of a broader biological role for A1CF and RBM47 in mammalian physiology. As noted above, our initial attempt to generate germline A1cf −/− mice revealed early developmental lethality with homozygous A1cf −/− blastocysts failing to implant at embryonic day 3.5 (Blanc et al. 2005) . A different line of A1cf −/− mice (used in the studies reported here) employed a distinct genomic targeting strategy (Snyder et al. 2017) and also used sox2-Cre which is active at embryonic day 6.5 and which would bypass the early, preimplantation lethality observed in our studies (Blanc et al. 2005 ; Moore al. 2014) . Those A1cf −/− mice were viable as adults yet showed abnormalities in renal function, while the viable heterozygous A1cf +/− mice from the initial knockout attempts demonstrated a growth phenotype with defective liver regeneration following partial hepatectomy ). Along the same lines, the original line of mutant, gene-trap Rbm47 −/− mice demonstrated perinatal lethality with the surviving animals showing a runted phenotype (Fossat et al. 2014) . Our findings used a different genomic targeting strategy and conditional tissue-specific deletion which again bypassed the perinatal lethality. While we observed no gross defects in liver or intestinal development in Rbm47 IKO , Rbm47 LKO , or the corresponding double knockout lines (i.e., AR IKO and AR LKO mice), we are currently examining in more detail the possibilities of other growth-related and metabolic phenotypes. As a final comment, we recognize that the current findings are limited to the tissue-specific impact of A1CF and of RBM47 within the liver and small intestine but we certainly acknowledge the importance of APOBEC1 dependent C-to-U RNA editing activity in other cell types as revealed by recent studies in microglia and monocytes derived from Apobec1 −/− mice (Cole et al. 2017; Rayon-Estrada et al. 2017) . We envision future studies utilizing a range of other cell-specific Cre drivers to elucidate the role of RBM47 in those contexts also.
MATERIALS AND METHODS
Animals
Rbm47 conditional knockout animals were generated by in vitro fertilization of C57BL/ 6 oocytes (Washington University Mouse Genetics Core) with sperm carrying the Rbm47 tm1a mutation (Rbm47 tm2a(EUCOMM) Wtsi ) obtained from the International Mouse Phenotyping Consortium/ European Mouse Mutant Archive (EMMA). Offspring were then bred with Flp-1 Tg mice (Jax# 009086) to remove the Frt-flanked LacZ-Neo cassette (Fig.  3A) . Genotyping was performed using the following primers surrounding the 3 ′ arm LoxP site: Rbm47 Fwd LoxP (P1) (5 ′ -ACT CCT GTG ACC CCT ACA CG-3 ′ ) and Rbm47 Rev 24157 (P2) (5 ′ -GTA ACC CAG GCT GGC CTA-3 ′ ), using the following conditions: 94°C for 5 min; 94°C for 30 sec, 60°C for 45 sec, 72°C for 50 sec (35 cycles); 72°C 10 min. The PCR reaction generates a 490 bp wild-type band and a 530 bp Rbm47 floxed (Rbm47 f/f ) band. Heterozygous intercrosses resulted in viable and fertile homozygous Rbm47 f/f mice with a normal Mendelian frequency. To generate liver-specific knockout mice (Rbm47 LKO ), Rbm47 tm1a mice were crossed with Albumin-Cre transgenic mice (Jax# 003570). Intestine-specific Rbm47 knockout (Rbm47 IKO ) were generated by crossing Rbm47 tm1a mice with transgenic villin-Cre-ER T2 mice (el Marjou et al. 2004) . Cre recombinase migration to the nuclear compartment was induced by intraperitoneal injection of 1 mg/ 100 µL tamoxifen (Sigma) 1 mg/day for 5 d (el Marjou et al. 2004) . All experimental and control animals were maintained on a C57BL/6J background.
A1cf tm1b (A1cf −/− ) were obtained from Jax (#005650) (Snyder et al. 2017 ) and maintained on a C57BL/6NJ background. Liver (AR LKO ) and intestine (AR IKO )-specific A1cf-Rbm47 double knockouts were generated by breeding A1cf −/− mice with Rbm47 LKO or Rbm47 IKO , respectively. Apobec-1 −/− mice were maintained on a C57BL/6J background. For hepatic overexpression of Apobec-1, animals were injected with 6 × 10 8 plaque-forming units of recombinant adenovirus encoding rat Apobec1 (Kozarsky et al. 1996) . Mice were 8-12 wk old and fed an ad libitum chow diet. All animals were treated according to the National Institutes of Health guidelines and all protocols were approved by the Washington University Institutional Animal Care and Use Committee.
RNA isolation, cDNA synthesis, and quantitative PCR
RNA was extracted from tissues of the indicated genotype using TRIzol (Invitrogen) following manufacturer's instructions. DNasefree RNAs (RNase-Free DNase kit, Qiagen) were used for cDNA preparation using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative evaluation of RNA abundance was performed using Fast SYBR Green Master Mix (Applied Biosystems) in a StepOne PLus Real Time PCR system instrument (Applied Biosystems). The following primers were used: A1cf: Fwd: 5 ′ -GCC AGA ATC CTCG CAA TCCA-3 ′ ; Rev 5 ′ -AGC ATA CCT CTT CGC TTC ATC C-3 ′ , Rbm47 Fwd: 5 ′ -GCT TCG CCT TTG TGG AGT ATG-3 ′ ; Rev: 5 ′ -ATC CGA CCTGGC ATG AG-3 ′ , ApoB Fwd: 5 ′ -CAC TGC CGT GGC CAA AA-3 ′ , Rev: GCT AGA GAG TTG GTC TGA AAA ATC CT-3 ′ . Total mRNA abundance was determined by normalization to Gapdh RNA level in each sample. Primers for Gapdh are as follows: Fwd: 5 ′ -TGTGTCCGT CGTGGATCTGA-3 ′ ; Rev: CCTGCTTCACCACCTTCTTGA-3 ′ .
RNA editing analysis by Sanger sequencing
Following reverse transcription, cDNA was used to amplify sequences containing Apobec-1-dependent editing sites previously identified in liver and small intestine (Blanc et al. 2014 ). PCR amplifications were performed using AccuPrime Pfx DNA polymerase (Thermo Fisher Scientific). Primer sequences are available (Blanc et al. 2014) . PCR products were then gel purified using Qiaquick Gel Extraction kit (Qiagen) and cloned using Zero Blunt TOPO PCR Cloning kit (Invitrogen) following manufacturer's recommendations. At least 20 individual clones were sequenced at Genewiz Inc.
Amplicon sequencing
PCR products of Apobec-1 hepatic and small intestine RNA targets were concatemerized as follows. The PCR products (∼12 ng) were treated with DNA polymerase I, Large Klenow Fragment (NEB) for 30 min at 37°C following manufacturer's instructions. After purification using PCR Purification kit (Qiagen), the PCR products were ligated overnight at room temperature using a mix of T4 DNA ligase and T4 polynucleotide kinase in the presence of 50% PEG-8000. Ligated products were purified using PCR Purification kit and ligation was confirmed by running aliquot of ligation on a 1% agarose gel. Concatemerized amplicons were then submitted for automated high-throughput DNA sequencing (Washington University Genome Center). The results of sequencing hepatic and intestinal amplicons are presented in Tables 1 and 2 .
Protein extraction and western blotting
Total liver and scraped intestinal mucosa were homogenized as previously described (Blanc et al. 2014) . Nuclear extracts were prepared using Glass Dounce Tissue homogenizer. Fifty milligrams of tissue was homogenized in 300 µL of Buffer A (25 mM Tris pH 7.5, 50 mM KCl, 2 mM MgCl 2 , 1 mM EDTA, 5 mM DTT, 1× protease inhibitor [Roche], 100 mM NaF, 1 mM NaVa, 50 mM α-glycerophosphate) performing 30 strokes with pestle A followed by 20 strokes with pestle B. The nuclear pellet was collected by centrifugation at 4000 rpm at 4°C for 10 min. The nuclei were washed three times with Buffer A, resuspended in 80 µL of Buffer B (25 mM Tris pH 7.5, 420 mM NaCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 1 mM DTT, 20% glycerol, 1× protease inhibitor) and incubated in ice for 30 min with a regular period of 30 sec vortex. Nuclear fraction was then collected by centrifugation 15 min at 10,000 rpm at 4°C. Fifteen micrograms of nuclear protein were resolved on a SDS-PAGE, transferred to PVDF membrane and probed with rabbit anti-A1CF antibody, rabbit anti-RBM47 (Abcam ab94638), anti-APOBEC1 (Kozarsky et al. 1996) . Equal loading was confirmed using a rabbit anti-actin antibody (Sigma-Aldrich).
For detection of hepatic apoB isoforms, liver tissue was homogenized using modified RIPA buffer containing 1 M urea (Smagris et al. 2016) . Fifty milligrams of tissue were suspended in 300 µL RIPA/urea buffer and homogenized in a bullet blender with 200 µL of 1 mm Glass Beads (Next Advance) twice for 5 min at maximum speed (speed 10) at 4°C. An additional 400 µL of RIPA/ urea buffer was added and the mixture homogenized at speed 3 for 3 min at 4°C. The Homogenates were supplemented with one tenth of the volume with 10× detergent buffer (10% SDS, 10% NP-40) and incubated in ice for 30 min, before centrifugation 15 min at 4°C 15,000 rpm. Eighty micrograms of extracts were then fractionated on a 4%-20% SDS gradient gel, transferred on PVDF membrane and probed with rabbit anti-apoB (1:4000). Equal loading was checked using rabbit anti-actin (1:2000) antibody.
In vitro RNA editing analysis by poisoned primer extension
A synthetic 360-nt apoB RNA (20 fmol) was incubated with liver extracts prepared from wild-type or A1cf-Rbm47 liver-specific double knockout (AR LKO ) mice. S100 extract (100 µg) or recombinant Apobec-1 (400 ng) was supplemented where indicated with increasing amounts (50 to 200 ng) of recombinant A1CF (Blanc et al. 2001) or recombinant mouse RBM47. Recombinant RBM47 protein was generated by cloning Rbm47 cDNA from mouse liver into the NdeI-XhoI sites of pTYB1 expression vector (New England Biolabs), resulting in synthesis of a C-terminal RBM47-intein fusion protein. RBM47 was purified as previously described (Blanc et al. 2001 ). S100 extracts with or without recombinant proteins were incubated for 3 h at 30°C in in-vitro conversion buffer (Blanc et al. 2001; Blanc and Davidson 2011) . Following incubation, RNA was phenol/chloroform extracted, precipitated and resuspended in cDNA synthesis reaction mix. Single-stranded DNA was then subjected to PCR amplification using the following apoB primers: Fwd:5 ′ -ATCTGACTGGGAGA GACAAGTAG-3 ′ , Rev: 5 ′ -GCTCGCTCAGGCTATATCTGTGG GC-3 ′ . PCR product was then used as template in poison primer extension as previously described (Blanc and Davidson 2011) . Extension products were separated by electrophoresis on a 7 M urea-acrylamide gel and analyzed by autoradiography.
